AstraZeneca says FDA accepts sBLA for self-administration FluMist Quadrivalent

AstraZeneca’s Supplemental Biologics License Application, or sBLA, for the approval of a self- or caregiver-administered option for FluMist Quadrivalent, a needle-free nasal spray, has been accepted for review by the U.S. Food and Drug Administration, the company announced. “If approved, FluMist will be the first flu vaccine available to be self-administered by eligible patients or administered by caregivers, adding an additional option to be vaccinated against influenza,” the company said.